The FDA has approved two new drugs of the thiazolidinedione class to treat type 2 diabetes mellitus. Rosiglitazone (Avandia, SmithKline Beecham, Philadelphia) is approved as monotherapy or in combination with metformin. Pioglitazone (Actos, Takeda Pharmaceuticals America Inc and Eli Lilly, Indianapolis) is approved as monotherapy or for use in combination with sulfonylureas, metformin, or insulin in patients whose disease is not adequately controlled by these agents alone. Patients taking either drug should follow a careful diet and try to achieve and maintain an appropriate weight.
Henney JE. New Type 2 Diabetes Drugs. JAMA. 1999;282(10):932. doi:10.1001/jama.282.10.932